NorthWest Biotherapeutics Inc (NWBO)

[sharpie510]

You may be right about what will or can be said with top line announcement and journal. But that surely won't be the case when they do follow up presentations at conferences. I am happy about the IDH wild-type and mesenchymal revelations because it mainly provides more clarity on how and why DCVax-L works. Dr. Ashkan said those DCVax-L patients who are in better prognostic groups are going to benefit more, but there is a benefit to all patients. I take that to mean IDH mutant (secondary glioblastoma), proneural, neural, and classical will also benefit; MGMT+ may benefit more than MGMT- in added months of survival but Marzan pointed out MGMT- actually benefits by almost the same percentage as MGMT+. That strengthens the argument that DCVax-L provides a benefit to all.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164010368